1. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. (June 2019) Authors: Mavratzas, A.; Baek, S.; Gerber, B.; Schmidt, M.; Moebus, V.; Foerster, F.; Grischke, E.M.; Fasching, P.; Strumberg, D.; Solomayer, E.; Klare, P.; Windemuth-Kieselbach, C.; Hartmann, S.; Schneeweiss, A.; Marmé, F. Journal: Breast Issue: Volume 45(2019) Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. (October 2020) Authors: Nuciforo, P.; Townend, J.; Saura, C.; de Azumbaja, E.; Hilbers, F.; Manukyants, A.; Werutsky, G.; Bliss, J.; Moebus, V.; Colleoni, M.; Aspitia, A.Moreno; Di Cosimo, S.; Van dooren, V.; Kroep, J.; Ferro, A.; Cameron, D.; Gelber, R.; Piccart-Gebhart, M.; Huober, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗